Pharmaceutical Technology

NOVEMBER 7, 2023

The UK National Institute for Health and Care Excellence (NICE) unveils refreshed support service, NICE Advice, for the life sciences sector.

Life Science 130

Life Science 130

Pharmaceutical Technology

NOVEMBER 17, 2022

The National Institute of Health and Care Excellence (NICE) has agreed to update its guidelines on endometriosis diagnosis, surgical management, and surgical management when fertility is a priority. The decision came following a surveillance review led by NICE, which identified sufficient new evidence to support this update.

Hormones 257

Hormones Compliance Research 257

Pharmaceutical Technology

NOVEMBER 20, 2022

The UK's National Institute for Health and Care Excellence (NICE) has published a draft guidance that does not recommend the use of five major Covid-19 therapies. The other two Covid-19 therapies that NICE rejected were two antivirals; Merck’s Lagevrio (molnupiravir) and Gilead Sciences’ Veklury (remdesivir).

Drugs 279

Drugs Medicine Antibody Clinical Trials 279

pharmaphorum

MARCH 5, 2024

NICE has rejected the use of AstraZeneca and Daiichi Sankyo’s Enhertu as an NHS treatment for advanced HER2-low breast cancer, a decision that the companies have described as “devastating”.

115

115

pharmaphorum

APRIL 11, 2024

AbbVie’s Aquipta has become the first oral therapy for chronic and episodic migraine prevention to be recommended by NICE for NHS use.

101

101

Pharmaceutical Technology

NOVEMBER 8, 2023

NICE is also working on incorporating real-world and AI-generated evidence into medicine evaluation submissions.

Medicine 147

Medicine 147

Outsourcing Pharma

APRIL 22, 2024

In a significant development for the multiple myeloma community, Menarini Stemline UK today welcomed the final draft guidance from the National Institute for Health and Care Excellence (NICE).

Development 80

Development Clinical Development 80

Pharmaceutical Technology

NOVEMBER 27, 2023

The UK NICE has recommended the usage of Alexion sebelipase alfa for the treatment of Wolman disease in infants and toddlers on the NHS.

130

130

pharmaphorum

APRIL 22, 2024

NICE backs wider NHS use of multiple myeloma drug Nexpovio Phil.Taylor Mon, 22/04/2024 - 10:58 Bookmark this

Drugs 95

Drugs 95

Pharmaceutical Technology

APRIL 24, 2023

The National Institute for Health and Care Excellence (NICE) has published a final draft guidance recommending the use of Darzalex (daratumumab) with bortezomib and dexamethasone (DVd) for adults with previously treated multiple myeloma.

Drugs 246

Drugs 246

Pharmaceutical Technology

APRIL 6, 2023

The UK’s National Institute for Health and Care Excellence (NICE) has published final draft guidance recommending AstraZeneca’s olaparib to treat early breast cancer and metastatic prostate cancer. It also updates NICE’s recommendation for olaparib for prostate cancer patients with BRCA1 or BRCA2 mutations.

Hormones 130

Hormones Medicine Development 130

pharmaphorum

MARCH 6, 2024

NICE has turned down Sanofi’s Xenpozyme as a treatment for the rare disease acid sphingomyelinase deficiency (ASMD), creating a situation where access to the drug in the UK will depend on a patient’s address.

Drugs 104

Drugs 104

pharmaphorum

JANUARY 18, 2024

Pfizer’s PARP inhibitor Talzenna has become the first targeted treatment for HER2-negative locally advanced or metastatic breast cancer with BRCA1/2 mutations to be recommended by NICE for routine NHS use.

109

109

pharmaphorum

JANUARY 25, 2024

NICE firms up guidance backing NHS use of five digital health wearables for remote monitoring of Parkinson's disease patients

109

109

Pharmaceutical Technology

NOVEMBER 17, 2022

The UK National Institute for Health and Care Excellence (NICE) has issued final guidance recommending using Takeda ’s mobocertinib (Exkivity) to treat advanced lung cancer. According to NICE, no standard treatment is currently available for exon 20 insertion mutation-positive NSCLC patients.

Gene 130

Gene Clinical Trials Clinical Trials Licensing 130

pharmaphorum

MARCH 7, 2024

NICE decision on Ipsen’s Cabometyx and MSD’s Keytruda in first-line kidney cancer ends a disparity in access within the UK.

104

104

Drug Discovery World

APRIL 22, 2024

The National Institute for Health and Care Excellence (NICE) has recommended Novartis’ Kymriah (tisagenlecleucel) for treating paediatric and young adults up to the age of 25 with B-cell acute lymphoblastic leukaemia (ALL). It is approved in cancers that are refractory, in relapse post-transplant or in second or later relapse.

Doctors 52

Doctors Doctor Drugs Trials 52

Pharmaceutical Technology

JUNE 5, 2023

The UK’s National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending the use of Bristol-Myers Squibb’s mavacamten (Camzyos) as an add-on to standard care to control symptoms of obstructive hypertrophic cardiomyopathy (HCM).

Medicine 130

Medicine Production Development 130

pharmaphorum

MARCH 19, 2024

Do better: The message to the industry from an analysis of clinical evidence submitted to NICE over 20 years Mike.Hammerton Tue, 19/03/2024 - 09:24 Bookmark this

122

122

pharmaphorum

DECEMBER 21, 2023

NICE backs NHS use of digital COPD rehab programmes, myCOPD and SPACE for COPD, as an alternative to face-to-face consultations

109

109

Pharmaceutical Technology

JULY 15, 2022

The UK National Institute for Health and Care Excellence (NICE) has recommended Novartis Pharmaceuticals UK’s Piqray (alpelisib) along with hormonal therapy fulvestrant to treat hormone receptor+, HER2-, PIK3CA-mutated locally advanced or metastatic breast cancer. By hindering this enzyme, the treatment could lower cancer growth and spread.

Hormones 147

Hormones Protein Gene Medicine 147

pharmaphorum

NOVEMBER 21, 2023

New NICE Advice service Mike.Hammerton Tue, 21/11/2023 - 09:00 Bookmark this

114

114

Pharmaceutical Technology

JANUARY 27, 2023

The UK National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending the use of Kite’s axicabtagene ciloleucel (yescarta) to treat aggressive forms of lymphoma. NICE medicines evaluation director Helen Knight said: “I am delighted that we have been able to recommend this pioneering treatment for people.

Gene Therapy 147

Gene Therapy Clinical Trials Clinical Trials Gene 147

Pharmaceutical Technology

NOVEMBER 24, 2022

The National Institute for Health and Care Excellence (NICE) in the UK has recommended Bristol Myers Squibb ’s (BMS) nivolumab (Opdivo) plus chemotherapy as an option for patients with advanced or metastatic gastric, gastro-oesophageal junction or oesophageal adenocarcinoma.

Protein 130

Protein Development Medicine 130

Pharmaceutical Technology

SEPTEMBER 26, 2022

The UK National Institute for Health and Care Excellence (NICE) has granted approval for Pfizer ’s palbociclib (Ibrance) in combination with anti-cancer therapy, fulvestrant, to treat advanced breast cancer patients. In addition to palbociclib, NICE has granted approval for 15 other therapies for breast cancer since 2018.

HR 130

HR Drugs Hormones Medicine 130

Pharmaceutical Technology

APRIL 27, 2023

The UK’s National Institute for Health and Care Excellence (NICE) has recommended two new personalised immunotherapy therapies from Kite Pharma to treat aggressive forms of blood cancer for the Cancer Drugs Fund (CDF). The new recommendation by NICE makes it available after only one therapy.

Gene Therapy 147

Gene Therapy Gene Clinical Trials Clinical Trials 147

pharmaphorum

JANUARY 11, 2024

NICE has extended the NHS availability of Pfizer’s COVID-19 drug Paxlovid as millions of doses approach their expiry date

Drugs 105

Drugs 105

Pharmaceutical Technology

MAY 18, 2023

The UK’s National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending AstraZeneca ’s dapagliflozin (Forxiga) to treat chronic heart failure. Today’s draft guidance means that for the first time, there is an effective treatment available on the NHS.

Medicine 130

Medicine 130

pharmaphorum

JANUARY 31, 2024

AbbVie’s CD20xCD3 bispecific antibody Tepkinly has been recommended by NICE for NHS use as a treatment for relapsed or refractory diffuse large B-cell lymphoma (DLBCL), an aggressive and fast-growing form of non-Hodgkin lymphoma. Tepkinly (epcoritamab) – the first medicine to emerge from AbbVie’s $3.9

Antibody 101

Antibody Medicine 101

Pharmaceutical Technology

APRIL 11, 2024

The oral drug, which gained UK approval in September 2023, is used for the prevention of both chronic and episodic migraines.

Drugs 244

Drugs 244

Outsourcing Pharma

FEBRUARY 22, 2024

The National Institute for Health and Care Excellence (NICE) has issued guidance recommending GSK's Omjjara (momelotinib) as a treatment option for disease-related splenomegaly.

Clinical Development 91

Clinical Development Development 91

pharmaphorum

JANUARY 23, 2024

Two artificial intelligence-powered software tools – e-Stroke and RapidAI – have been recommended for use in the NHS to help detect stroke from CT brain scans by NICE.

104

104

pharmaphorum

NOVEMBER 20, 2023

NICE to consult on inflation-busting fee increases Mike.Hammerton Mon, 20/11/2023 - 09:55 Bookmark this

117

117

Outsourcing Pharma

FEBRUARY 6, 2024

An artificial intelligence (AI)-powered tool from UK-based Brainomix was one of only two products to be endorsed by health assessor the National Institute of Health and Care Excellence (NICE).

Production 89

Production Regulation Marketing 89

Pharmaceutical Technology

AUGUST 19, 2022

The UK National Institute for Health and Care Excellence (NICE) has r ecommended Vifor Fresenius Medical Care Renal Pharma’s Tavneos (avacopan) plus rituximab or cyclophosphamide to treat adults with two ANCA-associated vasculitis (AAV) forms.

Clinical Trials 130

Clinical Trials Clinical Trials Trials Medicine 130

pharmaphorum

OCTOBER 26, 2023

NICE backs pump-based Parkinson’s drug from AbbVie Phil.Taylor Thu, 26/10/2023 - 10:14 Bookmark this

Drugs 111

Drugs 111

Pharma Times

FEBRUARY 21, 2023

Final draft guidance from NICE ensures people at highest risk will have access to COVID-19 therapies

141

141